LCAT
LCATproteinLCAT controls phospholipid and cholesterol ester metabolism on HDL, influencing net atherogenic lipid burden.
Pathway placement
Cascade stepLipid retention & oxidation
Confidencemedium
RationaleHDL-associated enzyme regulating cholesterol esterification; modulates lipoprotein metabolism and lipid homeostasis.
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000213398
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I33
C — confounder / Type-II68
A — assay feasibility68
E — evidence strength25
T1DI (composite)6
Specificity differential (R−C)-35
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(1)
- Lipidomic Approaches to Study HDL Metabolism in Patients with Central Obesity Diagnosed with Metabolic Syndrome.International journal of molecular sciences · 2022 · PMID 35743227 · doi
Omics datasets(1)
- PXD057196PRIDEApoA-I [human] (CSL112) infusion increases LCAT levels in HDL particles and promotes reverse cholesterol transport